Latest Conference Articles

The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.

Lynn M. Schuchter, MD, of Penn Medicine

ASCO 2024 Data Shake Up Standards and Shed Light on Biomarkers

July 16th 2024

This roundup includes exclusive insights from nearly 20 clinicians and key data on the top abstracts coming out of the 2024 ASCO Annual Meeting.

Laurence Albiges, MD, PhD

Belzutifan Yields PFS Advantage in Pretreated Advanced ccRCC Across Subgroups

July 12th 2024

Belzutifan generated superior efficacy and safety outcomes vs everolimus across prespecified subgroups of patients with previously treated advanced ccRCC.

Bradley A. McGregor, MD

Abemaciclib Monotherapy Does Not Elicit Responses in Advanced Renal Cell Carcinoma

July 12th 2024

Treatment with single-agent abemaciclib (Verzenio) did not demonstrate clinically meaningful activity in heavily treated patients with metastatic clear cell renal cell carcinoma.

Miso Kim, MD, PhD, Seoul National University Hospital

Fianlimab Plus Cemiplimab Yields Early Efficacy Signs in Pretreated Advanced ccRCC

July 12th 2024

Fianlimab plus cemiplimab produced durable responses in heavily pretreated advanced clear cell renal cell carcinoma.

Toni K. Choueiri, MD, of Dana-Farber Cancer Institute

Belzutifan Shows Manageable, Pooled Safety Profile in Advanced VHL-Associated RCC

July 12th 2024

Most patients included in the post-hoc pooled analysis who were treated with belzutifan experienced an all-cause adverse effect.

Karl Semaan, MD, MSc

Dr Semaan on Liquid Biopsy Epigenomic Profiling for the Detection of Sarcomatoid RCC

July 12th 2024

Karl Semaan, MD, MSc, discusses the utility of liquid biopsy epigenomic profiling for the detection of sarcomatoid renal cell carcinoma.

Bradley McGregor, MD, discusses findings from a phase 1b study of abemaciclib  in clear cell renal cell carcinoma.

Dr McGregor on the Data for Abemaciclib in Advanced ccRCC

July 12th 2024

Bradley McGregor, MD, discusses findings from a phase 1b study of abemaciclib in clear cell renal cell carcinoma.

Laurence Albiges, MD, PhD

Ongoing Research Aims to Identify Treatment Approaches for Non–Clear Cell RCC Subtypes

July 12th 2024

Laurence Albiges, MD, PhD, discusses research evaluating treatments for subtypes of non–clear cell renal cell carcinoma.

Neil J. Shah, MD, of Memorial Sloan Kettering Cancer Center

No OS Difference Observed After Various Immunotherapy/TKI Regimens in Advanced RCC

July 12th 2024

Real-world treatment patterns demonstrated that similar OS outcomes occurred for patients with renal cell carcinoma who received TKI- and immunotherapy-based regimens.

Toni K. Choueiri, MD

Dr Choueiri on the Phase 3 TiNivo-2 Study in Pretreated Advanced RCC

July 11th 2024

Toni K. Choueiri, MD, discusses the phase 3 TiNivo-2 study in pretreated advanced renal cell carcinoma.

Neil J. Shah, MBBS

Dr Shah on Remaining Unmet Needs in RCC After Frontline IO Combinations

July 11th 2024

Neil J. Shah, MBBS, discusses unmet needs for patients with RCC receiving immune-oncology–based combinations in the frontline setting.

Christopher Weight, MD, MS

Multimodal AI Approach May Help Identify Key Elements to Predict Outcomes in RCC

July 11th 2024

Using an AI tool for the collection and analysis of patient data may enhance the accuracy of outcome predictions and help personalize treatment plans.

Michael B. Atkins, MD

Nivolumab Plus Ipilimumab Yields Long-Term Efficacy Advantage in Advanced RCC

July 11th 2024

Nivolumab plus ipilimumab may generate positive long-term outcomes in patients with advanced renal cell carcinoma regardless of IMDC risk status.

 Francesco Sclafani, MD, PhD, of Institut Jules Bordet

REGINA Data Support Further Evaluation of Neoadjuvant Regorafenib, Nivolumab, and SCRT in Rectal Cancer

July 8th 2024

Data from the phase 2 REGINA trial support further investigation of neoadjuvant regorafenib, nivolumab, and SCRT in locally advanced rectal cancer.

Robert L. Coleman, MD, FACOG, FACS

Dostarlimab/Chemo Shows OS Benefit Regardless of MMR Status in Endometrial Cancer

July 3rd 2024

Dostarlimab plus chemotherapy demonstrated a meaningful overall survival improvement in primary endometrial cancer, regardless of mismatch repair status.

Kohei Shitara, MD, director, Department of Gastrointestinal Oncology, National Cancer Center Hospital East

Perioperative Pembrolizumab/Chemo Regimen Yields Superior OS in Resectable Gastric Cancer

July 2nd 2024

Patients with resectable gastric cancers achieved superior OS and pCR rates with perioperative pembrolizumab plus chemotherapy vs chemotherapy alone.

Eric Raymond, MD, PhD

First-Line Tislelizumab Plus Chemotherapy Shows OS Benefit in PD-L1+ ESCC Subgroups

July 2nd 2024

Tislelizumab plus chemotherapy improved OS in patients with unresectable esophageal squamous cell carcinoma and a CPS or TAP score of at least 1 vs 1%.

Jia (Jenny) Liu, MD, PhD, FRACP, senior research officer, ProCan Children’s Medical Research Institute; clinical lecturer, University of Sydney; conjoint senior lecturer, University of NSW, Kinghorn Cancer Centre, St Vincent’s Hospital

IBI343 Is Safe, Generates Preliminary Efficacy in CLDN18.2+ Advanced Gastric/GEJ Adenocarcinoma

July 2nd 2024

IBI343 was well tolerated and demonstrated signs of efficacy in patients with CLDN18.2-positive advanced gastric/GEJ adenocarcinoma.

Teresa Macarulla Mercade, MD, PhD

Mitazalimab/mFOLFIRINOX Is Tolerable, Generates Responses in Treatment-Naive mPDAC

July 2nd 2024

Mitazalimab plus mFOLFIRINOX yielded early efficacy signals and a manageable safety profile for the frontline treatment of patients with mPDAC.

Els Van Nieuwenhuysen, MD

Durvalumab Plus Olaparib Approaches EU Approval for pMMR Advanced or Recurrent Endometrial Cancer

July 1st 2024

The EMA recommends durvalumab plus chemotherapy, followed by olaparib and durvalumab for pMMR endometrial cancer, and single-agent durvalumab for dMMR disease.

Do-Youn Oh, MD, PhD

Durvalumab Plus Chemo Maintains OS Benefit in Advanced Biliary Tract Cancer

July 1st 2024

Durvalumab plus chemotherapy sustained an overall survival benefit vs chemotherapy alone in locally advanced or metastatic biliary tract cancer.

David Tougeron, MD, PhD

Pembrolizumab Plus Bevacizumab/CAPOX Yields Responses in pMMR/MSS mCRC With High TILs

July 1st 2024

Pembrolizumab plus bevacizumab and CAPOX produced responses in pMMR/MSS metastatic colorectal cancer with high immune infiltrate.

Markus Moehler, MD, PhD

TAP Score and CPS May Be Viable for PD-L1 Expression Measurement in Advanced Gastric Cancers

July 1st 2024

Concordance between TAP score and CPS at matched thresholds indicate their viability for assessing PD-L1 expression in advanced gastric cancers.

Kristen K. Ciombor, MD, MSCI

Nivolumab/Ipilimumab/Radiation Combo Produces Responses in Locally Advanced Rectal Cancer

July 1st 2024

The EA2201 trial evaluated nivolumab, ipilimumab, and short-course radiation therapy in patients with locally advanced rectal cancer.

Mehraneh D. Jafari, MD

Neoadjuvant Botensilimab/Balstilimab Is Active in Resectable Colon Cancer, Despite MMR Status

July 1st 2024

Botensilimab and balstilimab demonstrated pathological responses across subsets of patients with resectable colon cancer.

Dr Maximiliano Gelli, Gustave Roussy

TRANSMET Regimen Proves Safe, Feasible for Definitively Unresectable CRC Liver Metastasis

June 28th 2024

Liver transplantation plus chemotherapy demonstrated no concerning safety signals or long-term deterioration in QOL in patients with definitively unresectable CRC liver metastasis.

Gastric cancer | Image Credit: © Rasi - stock.adobe.com

Switch Ramucirumab/Paclitaxel Maintenance Yields Favorable Outcomes in HER2– Gastric Cancer

June 28th 2024

Switch ramucirumab/paclitaxel maintenance improved PFS and OS outcomes vs chemotherapy continuation in HER2-negative gastric or GEJ cancer.

Michel P. Ducreux, MD, PhD

TAS-102 Followed By Regorafenib Identified As Optimal Treatment Sequence in Pretreated mCRC

June 28th 2024

TAS-102 followed by regorafenib is an optimal sequence vs regorafenib followed by TAS-102 in select patients with metastatic colorectal cancer.

Sara Lonardi, MD

Frontline Nivolumab Plus Ipilimumab Reduces Symptomatic Burden in MSI-H/dMMR mCRC

June 28th 2024

HRQOL data from the CheckMate 8HW trial may support the use of nivolumab and ipilimumab as first-line treatment for patients with MSI-H or dMMR metastatic colorectal cancer.

Elisa Fontana, MD, PhD

Lunresertib Plus FOLFIRI Shows Safety, Elicits Responses in CCNE1+ or FBXW7+ Advanced GI Tumors

June 27th 2024

Lunresertib plus FOLFIRI was safe and produced responses in advanced gastrointestinal tumors harboring CCNE1 amplifications or FBXW7 alterations.